目的:对原发性肝癌TACE与RFA联合治疗的临床效果进行探索。方法:选取我院于2014年7月至2015年7月间收治的120例原发性肝癌患者作为研究对象,随机将其分为观察组和对照组,每组各60例,其中给予观察组患者TACE联合RFA治疗方法,给予对照组单独TACE治疗方法,对比分析两组方法的临床治疗效果。结果:经统计发现,首次治疗后观察组患者一个月联合组肿瘤完全坏死率为75%,对照组组肿瘤完全坏死率为38%,两组的肿瘤坏率存在统计学差异(P<0.05),差异具有统计学意义。复查期间观察组和对照组部分患者出现局部进展及复发,进行进一步TACE治疗及射频治疗,对照组患者肿瘤在第1、2、3年肿瘤进展率分别为50%、70%、95%;而观察组患者的肿瘤进展率分别为8%、42%、55%,两组差异显著(P<0.05),具有统计学意义。结论:TACE联合RFA治疗原发性肝癌能够取得较为理想的临床治疗效果,提高患者的康复速度,改善患者的生活治疗,以及提高患者的就医满意度,因此,值得在临床买践中推广应用。 Objective: To explore the clinical effect of combined treatment of TACE and RFA on primary liver cancer. Methods: A total of 120 patients with primary liver cancer who were treated in our hospital from July 2014 to July 2015 were selected as study subjects and randomly divided into observation group and control group, with 60 cases in each group. The patients in observation group Patients TACE combined with RFA treatment, control group given TACE alone treatment, comparative analysis of two groups of methods of clinical treatment. Results: After the first treatment, the complete tumor necrosis rate in the combined group was 75% in the observation group and 38% in the control group. There was a significant difference in the rate of tumor necrosis between the two groups (P <0.05) , The difference was statistically significant. During the review, some patients in the observation group and the control group showed local progression and recurrence, further TACE treatment and radiofrequency ablation. The tumor progression rates in the control group were 50%, 70% and 95% at the first, second, and third years, respectively The tumor progression rate in the observation group was 8%, 42% and 55% respectively, with significant difference between the two groups (P <0.05), with statistical significance. Conclusion: TACE combined with RFA in the treatment of primary liver cancer can achieve better clinical treatment, improve the recovery rate of patients, improve the life of patients and improve the patient’s medical satisfaction, so it is worth to promote the clinical application.